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Acute coronary syndrome (ACS) is a costly health care issue
worldwide.1 Numerous well-conducted clinical trials have
demonstrated that early intervention is associated with the
greatest long-term survival, better myocardial preservation,
and improved quality of life. Consequently, inpatient cardio-
vascular procedures in the United States have increased over
4-fold since 1979.1 Notably, the use of antiplatelet therapies
has increased well beyond this number and has affected the
management of the one-quarter million patients who un-
dergo cardiac surgery each year. The use of antithrombotic
agents carries a risk of minor and major bleeding, notably
when patients undergo coronary artery bypass grafting
(CABG) in the early phase of ACS, the time at which antith-
rombotic use is greatest and most effective. Concerns over
excess bleeding in patients undergoing CABG may lead to
withholding antiplatelet agents, perhaps sacrificing early
benefit for some patients. The use of blood products, notably
platelet transfusions, to treat bleeding has short- and long-
term risks that have not yet been balanced against the risks
of decreased myocardial survival associated with nonuse
of antiplatelet therapy. A better understanding of the risks
and benefits associated with early antiplatelet therapy is nec-
essary to improve the outcomes of all patients with ACS, in-
cluding those who undergo CABG.
VALUE OF EARLY INTERVENTION IN ACS
Numerous clinical trials conducted over 3 decades have
rigorously evaluated management strategies for ACS. These
studies have shown that early intervention combined with
appropriate antiplatelet agent use results in significantly
improved outcomes. The findings of these trials have been
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College of Cardiology/American Heart Association (ACC/
AHA) clinical guidelines for ACS management.2,3
Results of trials such as FRISC-II (Fast Revascularization
during Instability in Coronary artery disease-II),4 ISAR–
COOL (Intracoronary Stenting with Antithrombotic Regi-
men COOLing off),5 and ACUITY (Acute Catheterization
and Urgent Intervention Triage strategY)6 exemplify the
value of antiplatelet drugs in early ACS treatment. However,
the value of early coronary intervention accompanied by
profound inhibition of platelet aggregation and thrombus
formation incurs an increased risk of bleeding, which has
its own attendant morbidity and mortality. Despite the addi-
tional risk of bleeding, the use of appropriate pharmacother-
apy in patients with ACS is paramount. Recognition of both
the benefit of early interventional therapy in patients with
ACS with the simultaneous finding of benefit for antiplatelet
therapies has led to critical issues in developing strategies
that best combine these tactics while minimizing potential
risk. Central to this discussion is the following paradox: car-
diologists want intensive antiplatelet therapy, frequently
with multiple agents, to avoid thrombosis whereas surgeons
want to minimize antiplatelet therapy to avoid bleeding.
Thus, there is tension in balancing the risks of bleeding
and transfusion against improved long-term outcomes in
a frequently used treatment pattern for patients with ACS
consisting of early intervention and later CABG. Although
significant evidence exists to address this concern, it is
unclear whether the perception of bleeding risk with antipla-
telet agents is aligned with actual evidence for the real
risk-versus-benefit equation.
PLATELET INHIBITION AND THE RISK OF
BLEEDING
A wealth of clinical trial data provides evidence for the
benefit of antiplatelet therapy in preventing recurrent ische-
mia after ACS.7,8 This is a critical consideration in second-
ary prevention, particularly in the perioperative period when
platelet activity is high and associated with significant risk
for a second, potentially fatal ischemic event. It is therefore
imperative that a timely antiplatelet strategy be implemented
with due consideration for the potential and real risk of
abruptly stopping such beneficial therapy because of bleed-
ing concerns in patients undergoing CABG.
Intrinsic to any strategy for inhibiting platelet function
is the increased risk for bleeding. Bleeding is usually classi-
fied according to clinical or laboratory criteria as major
(life-threatening, severe) or minor.9 However, bleedingardiovascular Surgery c Volume 138, Number 4 807
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much as a 3-fold difference in the reported incidence ofmajor
bleeding (Figure 1).10 Points of discrepancy between criteria
for major bleeding include a decrease in hemoglobin (from
 3 g/dL to  5 g/dL), a requirement for transfusion ( 1
unit or  2 units), or a requirement for an overt source of
bleeding.10
A growing body of evidence shows that, regardless of the
classification system applied, bleeding is an independent pre-
dictor of adverse clinical outcomes. TIMI (Thrombolysis In
Myocardial Infarction)major bleeding, GUSTO (Global Uti-
lization of Strategies ToOpen occluded arteries) moderate or
severe bleeding, and a drop in hemoglobin have all been as-
sociated with early mortality and/or other adverse cardiovas-
cular events within 30 days10; whether such bleeding is also
associated with mortality at 6 months or 1 year is currently
unclear. Thus, the prevalence and risk for bleeding in patients
with ACS with or without intervention, remains a significant
concern requiring careful consideration to balance the risk of
bleeding with the benefit of antiplatelet therapies.
ANTIPLATELET THERAPIES AND
INTERVENTION
Based on the importance of antiplatelet therapy in treating
ACS, evidence-based guidelines for their use have been pre-
pared.2,3 Because aspirin and clopidogrel are the only anti-
platelet therapies currently recommended at a class I level
for both immediate and long-term use in patients with
ACS they will be the main focus of the remaining
discussion.
Historically, the benefits of early aspirin use in the treat-
ment of patients with ACS have been well established.11
For patients undergoing CABG preoperative aspirin use
has been associated with improved graft patency and re-
duces the risk of perioperative myocardial infarction (MI),
FIGURE 1. Differences in risk of bleeding in patients who underwent cor-
onary artery bypass grafting in the Clopidogrel in Unstable angina to pre-
vent Recurrent Events (CURE) trial depending on the bleeding definition
used. All P values> .05. GUSTO, Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coronary Arteries; TIMI,
Thrombolysis In Myocardial Infarction. Adapted with permission.10808 The Journal of Thoracic and Cardiovascular Surin-hospital mortality, and other adverse postoperative out-
comes (Table E1).
Older aspirin studies sparked debate around aspirin use in
CABG inasmuch as they showed that preoperative aspirin
use was associated with increased blood loss, greater trans-
fusion rates, and higher re-exploration rates (Table E2).
However, numerous subsequent studies have described no
significant increase in bleeding complications in patients
undergoing CABG receiving aspirin in the 7 days before sur-
gery (Tables E2 and E3). Thus, aspirin is not a significant
risk factor for bleeding or transfusion.
The efficacy of dual antiplatelet therapy with aspirin and
clopidogrel has been compared with aspirin monotherapy in
patients with ACS and those undergoing percutaneous coro-
nary intervention (PCI). The results of these large, prospec-
tive, randomized trials show that adding clopidogrel to
aspirin consistently reduces the risk of adverse events, in
most cases, without significantly increasing the risk of
bleeding (Table E4). Overall, there is a clear, consistent ben-
efit associated with clopidogrel pretreatment before PCI, and
the reduction in cardiovascular events before PCI suggests
that clopidogrel pretreatment should be initiated as soon as
possible. Although the risk of bleeding may be greater
with dual antiplatelet therapy, the excess risk is not enough
to outweigh the benefits.
Data also suggest that aspirin and clopidogrel improve
clinical outcomes without being associated with increased
bleeding after CABG.12,13 Among the 1013 patients in the
CURE (Clopidogrel in Unstable angina to prevent Recurrent
Events) study who received CABG during their index hospi-
talization, dual antiplatelet therapy reduced the relative risk
of cardiovascular death, MI, and stroke by 19% compared
with patients who received aspirin alone (relative risk,
0.81; 95% confidence interval [CI], 0.59–1.12); the bulk
of this benefit was due to an 18% reduction in the relative
risk of events occurring before surgery (relative risk, 0.82;
95% CI, 0.58–1.16).12 Among the 136 CLARITY (Clopi-
dogrel as Adjunctive ReperfusIon TherapY) patients who
underwent CABG, dual therapy with aspirin and clopidogrel
reduced the risk of cardiovascular death, MI, and recurrent
ischemia by 34% compared with those who received aspirin
(odds ratio, 0.66; 95% CI, 0.27–1.63), a benefit due entirely
to a reduction in MI and recurrent ischemia before surgery
(odds ratio, 0.46; 95% CI, 0.16–1.36).13 Results of other
studies disagree with those of CURE and CLARITY inas-
much as they show an increased risk of procedural bleeding,
re-exploration, blood product usage, and chest drain blood
loss in patients undergoing CABG receiving clopidogrel
and aspirin, particularly within 5 to 7 days of the operation
(Tables E2 and E3).
THE CABG CONUNDRUM
Only 7% to 12% of patients with non–ST-elevation MI
and 4% of patients with ST-elevation MI undergogery c October 2009
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are done on an emergency basis (immediately after failed
PCI).16 Given that CABG is performed in only a minority
of patients, is effective antiplatelet treatment being withheld
from the majority for the benefit of the minority?
The preponderance of evidence indicates that clopidogrel
exposure within 5 to 7 days of CABG is associated with
excess bleeding (Tables E2 and E3); thus, current guide-
lines recommend a clopidogrel washout period of 5 to 7
days before planned CABG.2,3 However, it is not clear
how clopidogrel-associated excess bleeding has affected
CABG clinical practice. Although transfusion rates are
driven by institutional and practitioner preferences, they
do provide some estimation of bleeding after CABG sur-
gery. Thus, one way to loosely assess the effect of escalated
platelet inhibition on CABG clinical practice is to examine
the transfusion requirements reported for different antiplate-
let regimens (Tables E2 and E3). Caveats to such compar-
isons include the potential masking effect of advancing
surgical techniques,17 the varying transfusion thresholds
among hospitals,18 the nonhomogeneous use of antiplatelet
regimens perioperatively,19 and physician biases toward
prophylactic, and perhaps unnecessary, transfusion of
plasma and platelets in clopidogrel-treated patients.18 Given
these caveats, observational data suggest that transfusion
rates for patients undergoing CABG have remained rela-
tively unchanged in the dual antiplatelet therapy era. In
the early days of CABG, almost all patients received a trans-
fusion.20 With the advent of hemodilution and concerns
over the quality of the blood supply, efforts were made to
reduce blood transfusions throughout the 1980s and be-
yond. Examination of the data shows that although the
amount of blood loss has increased anywhere from 30%
to 100% along with escalated platelet inhibition, the per-
centage of patients receiving transfusions (between 20%
and 60% depending on the study) and the amount of blood
transfused per patient (mean of 2 to 3 units) has remained
approximately the same (Tables E2 and E3). For this issue
to be addressed more effectively, however, there is a need
for prospective collection of post-CABG bleeding and
transfusion rates in all clinical trials of antiplatelet agents.
The percentage of patients who have an adverse myocar-
dial event while waiting for clopidogrel washout is not
known. Although data from some studies support the
CURE and CLARITY findings that fewer clopidogrel-
exposed patients have adverse outcomes, data from other
studies suggest the opposite.19,21 It is possible to extrapolate
data from PCI–CURE, in which the time to PCI was 6 days
and the incidence of an MI while waiting for intervention
was 5.1% in the placebo group and 3.6% in the clopidogrel
group (P ¼ .04; number needed to treat ¼ 66 to prevent an
MI before PCI). Such an extrapolation suggests that the
reduction in blood loss, risk of re-exploration, and blood
product usage that accompanies cessation of clopidogrelThe Journal of Thoracic and Cfor 5 to 7 days before CABG comes at the expense of
approximately a 1% increase in the risk of MI while waiting
for surgery.22 This rate may be highest in the period imme-
diately after the first ACS event and may decline in the
weeks or months that precede elective CABG.
Whether a reduced risk of bleeding is worth an in-
creased risk of additional ischemic events remains an issue
for continued debate. Adding to this debate are important
considerations regarding the direct and indirect economic
and social costs of hospitalization on patients and their
families resulting from potentially unnecessary delays
in CABG. In one study comparing resource use in
a CABG patient cohort, the costs for those who underwent
nonelective CABG were 33% higher than the costs for
those who underwent elective CABG, a difference due
almost entirely to costs incurred during a longer preoper-
ative length of stay.23 Prolonged lengths of stay also ex-
pose patients, particularly those who are elderly, to the
development of comorbid conditions related to long hospi-
tal stays, including decubitus ulcers (bed sores) and noso-
comial infections. One way to limit the overall impact of
a clopidogrel washout period may be to discharge patients
to home, as results of a retrospective analysis of
125 patients who received CABG within 3 to 5 days of
clopidogrel cessation showed that those discharged to
home had similar intraoperative and postoperative out-
comes as those who remained hospitalized.24 Overall, ad-
ditional information on the risks of clopidogrel washout
before CABG is needed.
FUTURE DIRECTIONS
The absence of reliable, easy, and quick platelet function
testing for patients receiving a wide variety of antiplatelet
drugs is a serious problem. There are several commercially
available platelet function tests, but the overall utility of
platelet function testing is limited by poor reproducibility
and comparability among tests. Variability in response to
antiplatelet agents, perhaps especially marked for the pro-
drugs, makes estimation of dosing and timing of antiplatelet
administration very difficult. Furthermore, if physicians
were able to more precisely determine which patients were
at the greatest risk of bleeding, as well as the time at which
antiplatelet-exposed patients could be safely operated on,
appropriate upstream initiation of therapy might increase.
For such a scenario to come to fruition, a single reproducible
and inexpensive test to measure platelet inhibition is
necessary.
CONCLUSION
Antiplatelet therapy is a mainstay of care for patients with
ACS, and the majority of these patients benefit from its early
use, as evidenced by a reduced risk of cardiovascular events
while awaiting interventional revascularization. The vast
majority of patients with ACS receive PCI as opposed toardiovascular Surgery c Volume 138, Number 4 809
Expert Commentary Aranki and BodyCABG; therefore, waiting to confirm coronary anatomy be-
fore initiating antiplatelet therapy would be to the detriment
of 90% to 95% of patients if one considers that only 5% to
12% of patients with ACS undergo CABG.14,15
Although antiplatelet therapy is associated with clinical
benefit in patients undergoing CABG, it also increases the
risk of bleeding in some, but not all, patients. Although pro-
longed cessation of clopidogrel in patients undergoing
CABG before the procedure is associated with a reduction
in perioperative blood loss and blood product usage and a
reduced risk of re-exploration, these benefits come at the
expense of a 1% increase in the risk of MI while awaiting
surgery.22 Inasmuch as previous bleeding concerns associated
with aspirin use before CABG have been overcome with in-
creased clinical experience, the risk of bleedingwith dual anti-
platelet therapy may be reduced with increased operator
experience and adjunctive therapeutic agents such as the ly-
sine analogs to reduce surgical bleeding. Overall, strategies
aimed at reducing the risk of bleeding should not compromise
the clinical benefit of antiplatelet therapy. In the future, platelet
function testing may increase the use of appropriate upstream
antiplatelet therapy by helping surgeons determine when the
risk of bleeding is lessened in antiplatelet-exposed patients.
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Aranki and Body Expert CommentaryTABLE E1. Benefit of aspirin after CABG
Study Patients
Outcome in
ASA recipients
Outcome in ASA
nonrecipients Risk reduction
Goldman et alE1 406 men who
underwent elective
CABG followed by
coronary angiography
at 1 year (299 received
ASA, 107 did not)
15.8% of grafts were
occluded on angiography
22.6% of grafts were
occluded on angiography
(P ¼ .029 vs those
who received ASA)
Not reported
Dacey et alE2 1056 CABG recipients
(368 received ASA,
688 did not)
31% experienced
in-hospital death
37% experienced
in-hospital death
ASA reduced the risk of in-
hospital death by 45% on
multivariate analysis (OR,
0.55; 95% CI, 0.31–0.98;
P ¼ .04)
Brown et alE3 127 CABG patients who
underwent CABG
followed by coronary
angiography at 1 year
(38 received ASA
alone, 45 received
ASAþDP, 44
received placebo)
12% of grafts in ASA-only
recipients were occluded
14% of grafts in ASA
þDP recipients
were occluded
21% of grafts
were occluded
ASA alone reduced the odds of
occlusion at 1 year by 53%
(OR, 0.47; P ¼ .04)
ASAþDP reduced the odds of
occlusion at 1 year by 50%
(OR, 0.50; P ¼ .04)
Gavaghan
et alE4
231 patients who
underwent CABG
followed by coronary
angiography at 1 week
(126 received ASA,
105 did not)
4.0% of grafts were
occluded
14.3% of grafts were
occluded (P ¼ .003
vs those who received ASA)
Not reported
Gavaghan
et alE4
219 patients who
underwent
CABG followed by
coronary angiography
at 1 year (119 received
ASA, 100 did not)
11.9% of grafts were
occluded
29.5% of grafts were
occluded (P< .002
vs those who received
ASA)
Not reported
ManganoE5 5022 CABG recipients
(2999 received ASA,
2023 did not)
1.3% experienced
in-hospital all-cause
death;
1.1% experienced
in-hospital cardiac
death;
2.8% experienced
in-hospital MI;
1.3% experienced
in-hospital stroke
4.0% experienced
in-hospital all-cause
death;
3.1% experienced
in-hospital cardiac
death;
5.4% experienced
in-hospital MI;
2.6% experienced
in-hospital stroke
ASA significantly reduced
the odds of in-hospital
all-cause mortality,
cardiac mortality, MI,
and stroke (P  .01
for each)
ASA, Aspirin; CABG, Coronary artery bypass grafting; CI, confidence interval; DP, dipyridamole; MI, myocardial infarction; OR, odds ratio.The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 4 810.e1
Expert Commentary Aranki and BodyTABLE E2. Blood loss, blood product usage, and rates of reoperation for bleeding in the different eras of antiplatelet therapy
Study Blood lost (mL)
Reoperation
for bleeding
(n;%)
Blood
transfused
(U/patient;%)
FFP
transfused
(U/patient;%)
Platelets
transfused
(U/patient;%)
A. Studies comparing aspirin vs no aspirin
Michelson et alE6 ASA: 919491a,b
No ASA: 437244a
NR ASA: 1.11.3a; 55.6
No ASA: 1.31.5a; 68.8
NR NR
Ferraris et alE7 ASA: 1513977a,b,c
No ASA: 916482a,c
ASA: 2; 12.5
No ASA: 0
ASA: 4.43.5a,b
No ASA: 1.81.3a
ASA: 3.64.9a,b
No ASA: 0.71.6a
ASA: 1.31.3a,b
No ASA: 0.160.38a
Taggart et alE8 75 ASA: 1150
(820, 1380)b,d
150 ASA: 1360
(1020, 1730)b,d
300 ASA: 1100
(810, 1340)b,d
No ASA: 870
(790, 960)d
ASA: 7; 6.9
No ASA: 6; 5.9
75 ASA: 4.0 (2.5, 4.5)b,e
150 ASA: 4.0 (2.5, 5.0)b,e
300 ASA: 3.0 (1.5, 4.5)b,e
No ASA: 2.0 (1.5, 2.5)e
NR NR
Goldman et alE9 325 ASA: 965b,e
325 ASA tid: 1175b,e
ASA/DP: 1000b,e
Sulf: 775e
Placebo: 805e
325 ASA: NR; 9.3f
325 ASA tid: NR; 6.3f
ASA/DP: NR; 3.9f
Sulf: NR; 2.1
Placebo: NR; 1.3
NR NR NR
Dacey et al (a)E2 ASA: 13182078a
No ASA: 12551498a
ASA: NR; 32.9
No ASA: NR; 33.0
ASA: 3.04.1a
No ASA: 3.34.3a
ASA: 3.45.7a
No ASA: 3.55.5a
ASA: 3.68.3a
No ASA: 5.410.6a
Dacey et al (b)E2 ASA: 822590a
No ASA: 799774a
ASA: NR; 7.1
No ASA: 8.1
ASA: 1.41.7a
No ASA: 1.42.0a
ASA: 0.91.9a
No ASA: 1.12.9a
ASA: 1.13.3a
No ASA: 1.24.0a
Kallis et alE10 ASA: 1185b,g
Placebo: 791g
ASA: 4b; 8
No ASA: 0
ASA: 3.1b,g
No ASA: 2.1g
ASA: 0.4b,g
No ASA: 0g
ASA: 0.5b,g
No ASA: 0g
Tuman et alE11 ASA: 627388a
No ASA: 658465a
ASA: 4; 1.3
No ASA: 0
ASA: 1.41.9a
No ASA: 1.32.0a
ASA: 0.51.3a
No ASA: 0.41.1a
ASA: 0.51.2a
No ASA: 0.51.1a
Vuylsteke et alE12 ASA: 685327a
No ASA: 654289a
ASA: 1; 1.2
No ASA: 1; 1.7
ASA: 1.11.8a
No ASA: 1.53.2a
ASA: 0.10.6a
No ASA: 0.20.2a
ASA: 0.20.5a
No ASA: 00.8a
B. Studies comparing clopidogrel vs no clopidogrel
Hongo et alE13 CLO: 11241119a,b
No CLO: 775727a
CLO: 4; 6.8b
No CLO: 1; 0.6
CLO: 2.512.41a,b; 79.7b
No CLO: 1.742.16a; 50.8
CLO: 0.681.69a,b
No CLO: 0.240.85a
CLO: 0.861.20a,b; 50.8b
No CLO: 0.240.60a; 18.2
Englberger et alE14 CLO: 1485310a,b
No CLO: 780105a
CLO: 8; 5.9b
No CLO: 5; 1.2
CLO: 4.62.3a,b; 92b
No CLO: 1.52.2a; 47
CLO: 0.91.4a; 42b
No CLO: 0.30.9a; 13
CLO: 2.61.1a,b; 71b
No CLO: 0.20.6a; 9
Karabulut et alE15 CLO: 719265a
No CLO: 612350a
CLO: 0
No CLO: 16; 1
CLO: 0.50.9a
No CLO: 0.40.9a
CLO: 1.11.2a
No CLO: 0.91.1a
NR
Kapetanakis et alE16 CLO: 400 (100–6000)h
No CLO: 400
(100–2000)h
CLO: 24; 5.8b
No CLO: 25; 1.3
CLO: 2.0
(1.0–8.0)b,h; 30.4b
No CLO: 2.0
(1.0–7.0)h; 22.1
CLO: 1.5 (0.8–3.1)h; 3.9b
No CLO: 1.9 (0.1–3.8)h; 1.6
CLO: 0.7 (0.6–1.2)h; 5.1b
No CLO: 0.7 (0.2–1.3)h; 1.8
Mehta et al (a)E17 NR NR CLO: 2 (0, 4)b,i
No CLO: 1 (0, 3)i
NR CLO: NR; 33.7b
No CLO: NR; 20.3
Mehta et al (b)E17 NR NR CLO: 2 (0, 4)i
No CLO: 2 (0, 4)i
NR CLO: NR; 17.7
No CLO: NR; 15.0
Berger et alE18 NR CLO: 14; 4.7b
No CLO: 4; 1.3
NR NR NR
Kim et alE19 NR CLO: 11; 3.3
No CLO: 116; 2.6
CLO: NR; 70.2
No CLO: NR; 68.2
NR NR
C. Studies comparing other antiplatelet regimens (combination vs monotherapy, antiplatelet vs no antiplatelet, different time frames of
antiplatelet exposure)
Yende and
WunderinkE20
NR ASAþCLO:
5; 10.4j
ASA: 3; 2.3j
Neither: 0j
ASAþCLO: 2.9g,k; 70.8k
ASA: 1.8g; 53.9
Neither: 1.1g; 46.9
ASAþCLO: 1.2g; 31.3
ASA: 0.7g; 23.9
Neither: 0.5g; 17.2
ASAþCLO: 4.6g,k
ASA: 2.1g
Neither: 0.7g
Ray et alE21 NR NR ASAþCLO: 2.42.3a,j
ASA: 1.92.4a,j
CLO: 2.93.4a,j
Neither: 1.42.0a
ASAþCLO: 3.15.4a,j
ASA: 2.34.4a,j
CLO: 2.55.4a,j
Neither: 1.62.9a
ASAþCLO: 3.75.2a,j
ASA: 1.33.1a,j
CLO: 3.66.0a,j
Neither: 1.03.7a,j810.e2 The Journal of Thoracic and Cardiovascular Surgery c October 2009
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Study Blood lost (mL)
Reoperation
for bleeding
(n;%)
Blood
transfused
(U/patient;%)
FFP
transfused
(U/patient;%)
Platelets
transfused
(U/patient;%)
Leong
et al (a)E22
ASAþCLO: 503 (225–
1230)h
ASA: 570 (100–3675)h
CLO: 573 (140–1365)h
Neither: 503 (225–1230)h
ASAþCLO: 0
ASA: 0
CLO: 0
Neither: 0
ASAþCLO: 0 (0–0)h
ASA: 0 (0–4)h
CLO: 0 (0–2)h
Neither: 0 (0–10)h
ASAþCLO: 0 (0–0)h
ASA: 0 (0–2)h
CLO: 0 (0–0)h
Neither: 0 (0–0)h
ASAþCLO: 0 (0–0)h
ASA: 0 (0–6)h
CLO: 0 (0–0)h
Neither: 0 (0–0)h
Leong
et al (b)E22
ASAþCLO: 803
(300–3780)h,k
ASA: 620 (58–4500)h
CLO: 585 (200–1755)h
Neither: 603 (50–2908)h
ASAþCLO: 27; 3.4
ASA: 1; 1.5
CLO: 0
Neither: 1; 0.5
ASAþCLO: 1 (1–30)h
ASA: 1 (0–12)h
CLO: 1 (0–10)h
Neither: 1 (0–21)h
ASAþCLO: 0 (0–4)h
ASA: 0 (0–11)h
CLO: 0 (0–2)h
Neither: 0 (0–3)h
ASAþCLO: 0 (0–5)h
ASA: 0 (0–6)h
CLO: 0 (0–1)h
Neither: 0 (0–7)h
Nurozler
et alE23
ASAþCLO:
1180280a,j
ASA: 660110a,j
CLO: 1210260a,j
Neither: 62590a
ASAþCLO: 3; 6.1j
ASA: 1; 1.4j
CLO: 2; 7.1j
Neither: 0
ASAþCLO: 3.90.8a,j
ASA: 1.40.3a,j
CLO: 3.71.0a,j
Neither: 1.20.4a
ASAþCLO: 1.40.6a,j
ASA: 0.70.4a,j
CLO: 1.30.7a,j
Neither: 0.40.3a
ASAþCLO: 2.01.2a
ASA: 0.20.5a
CLO: 2.21.1a
Neither: 0.30.4a
Hekmat
et alE24
APT: 1123573a,b
No APT: 874351a
APT: 4; 2.8
No APT: 5; 3.4
APT: 2.62.5a,b
No APT: 1.61.8a
APT: 2.02.2a,b
No APT: 1.32.0a
APT: 1.21.8a,b
No APT: 0.20.8a
Shim et alE25 APT 6 d: 265146a,l
APT 3-5 d: 330191a,l
APT 2 d: 323187a,l
APT 6 d: 756408a,m
APT 3-5 d: 729485a,m
APT 2 d: 627257a,m
NR APT 6 d: 1.11.8a; 39
APT 3–5 d: 1.90.8a; 48
APT 2 d: 1.61.9a; 26
APT 6 d: NR; 11
APT 3–5 d: NR; 8
APT 2 d: NR; 5
APT 6 d: NR; 0
APT 3–5 d: NR; 2
APT 2 d: NR; 5
If no percentage is reported, it was not available in the original manuscript. For details of the individual studies (study design, number of subjects, and antiplatelet regimens studied),
see Table E4. APT, Antiplatelet; ASA, aspirin; CABG, coronary artery bypass grafting; CLO, clopidogrel; d, day; DP, dipyridamole; FFP, fresh frozen plasma; NR, not reported;
sulf, sulfinpyrazone; tid, three times daily. aMeanstandard deviation; bP  .05 vs control; c12 hours postoperative; dmean (95% confidence interval); emedian (95% confidence
interval); fP<.01 for all ASA vs no ASA; gmean; hmedian (range); imedian (interquartile range); jP  .05 for trend; kP  .05 vs no ASA; lin the operating room; m24 hours post-
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Expert Commentary Aranki and BodyTABLE E3. Details of studies reporting correlations between aspirin and clopidogrel therapy and blood loss, blood product usage and reoperation
for bleeding
Study reference Description Total (N) Antiplatelet regimen (n)
Berger et al. J Am Coll Cardiol.
2008;52:1693-701E18
Retrospective, multicenter study of
patients who underwent CABG
within 7 d of ACS
596 CLO 5 d before CABG (298)a
No CLO (298)
Dacey et al. (a) Ann Thorac Surg.
2000;70:1986-90E2
Retrospective, multicenter, case–
control study of patients who died
after CABG
368 ASA (114)
No ASA (254)
Dacey et al. (b) Ann Thorac Surg.
2000;70:1986-90E2
Retrospective, multicenter, case–
control study of patients who
survived CABG
688 ASA (254)
No ASA (434)
Englberger et al. Eur J Cardiothorac
Surg. 2004;26:96-101E14
Prospective, single-site study of
patients undergoing consecutive
CABG procedures
505 CLO 72 h before CABG (136)b
No CLO (369)
Ferraris et al. Ann Thorac Surg.
1988;45:71-4E7
Nonblinded, single-site randomized
study of patients undergoing
CABG procedures
34 ASA the day before surgery (16)
No ASA (18)
Goldman et al. Circulation.
1988;77:1324-32E9
Randomized, multicenter study of
patients undergoing CABG
procedures
772 325 mg/d ASA<48 h of surgery (154)
325 mg tid ASA (155)
325 mg ASAþ75 mg DP tid (162)
267 mg tid sulf (148)
Placebo (153)
Hekmat et al. Curr Med Res Opin.
2004;20:1429-35E24
Retrospective, single-site study of
patients undergoing CABG
procedures
290 APT 5 d before CABG (145)
No APT (145)
Hongo et al. J Am Coll Cardiol.
2002;40:231-713
Prospective, single-site study of
patients undergoing CABG
procedures
224 CLO 7 d before CABG (59)c
No CLO (165)
Kallis et al.Eur J Cardiothorac Surg.
1994;8:404-9E10
Randomized, single-site study of
patients undergoing elective
CABG procedures
100 300 mg/d ASA until time of surgery (50)
Placebo (50)
Kapetanakis et al. Eur Heart J.
2005;26:576-83E16
Retrospective, single-site study of
patients undergoing CABG
procedures
2359 CLO 7 d before CABG (415)a
No CLO (1944)
Karabulut et al. Eur J Cardiothorac
Surg. 2004;25:419-23E15
Retrospective, single-site study of
CABG procedures
1628 CLO 2 d before CABG (48)d
No CLO (1580)
Kim et al. Am Heart J.
2008;156:886-92E19
Retrospective, single-site study of
CABG procedures
4794 CLO 5 d before CABG (332)e
No CLO (4462)
Leong et al. (a) Ann Thorac Surg.
2005;80:928-33E22
Retrospective, single-site study of
patients undergoing OPCABG
procedures
109 ASAþCLO 7 d before CABG (2)
ASA alone (75)
CLO alone (6)
Neither drug (26)
Leong et al. (b) Ann Thorac Surg.
2005;80:928-33E22
Retrospective, single-site study of
patients undergoing CABG CPB
procedures
810 ASAþCLO 7 d before CABG (59)
ASA alone (523)
CLO alone (18)
Neither drug (210)
Mehta et al. (a) J Am Coll Cardiol.
2006;48:281-6E17
Retrospective, multisite study of
patients undergoing CABG
procedures performed 5 d of
symptom onset
2565 CLO (739)f
No CLO (1826)
Mehta et al. (b) J Am Coll Cardiol.
2006;48:281-6E17
Retrospective, multisite study of
patients undergoing CABG
procedures performed>5 d after
symptom
293 CLO>5 d before CABG (113)g
No CLO (180)810.e4 The Journal of Thoracic and Cardiovascular Surgery c October 2009
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Study reference Description Total (N) Antiplatelet regimen (n)
Michelson et al. J Thorac
Cardiovasc Surg. 1978;76:
694-7E6
Retrospective, single-site study of
patients undergoing CABG
procedures
25 ASA in the week before surgery (9)
No ASA (16)
Nurozler et al. Interact Cardiovasc
Thorac Surg. 2005;4:546-9E23
Retrospective, single-site study of
patients undergoing CABG
procedures
182 ASAþCLO 3 d before CABG (49)
ASA alone (68)
CLO alone (28)
Neither drug (37)
Ray et al. BMC Cardiovasc Disord.
2003;3:3E21
Retrospective, multisite study of
patients undergoing CABG
procedures
659 ASAþCLO 7 d before CABG (46)
ASA alone (105)
CLO alone (11)
Neither drug (497)
Shim et al. J Thorac Cardiovasc
Surg. 2007;134:59-64E25
Prospective, single-site study of
patients undergoing OPCABG
procedures
106 ASAþCLO 6 d before CABG (35)
ASAþCLO 3–5 d before CABG (51)
ASAþCLO 2 d before CABG (20)
Taggart et al. Ann Thorac Surg.
1990;50:424-8E8
Prospective, single-site study of
consecutive patients undergoing
CABG procedures
202 75 mg/d ASA at time of surgery (44)
150 mg/d ASA (28)
300 mg/d ASA (29)
No ASA (101)
Tuman et al. Anesth Analg.
1996;83:1178-84E11
Prospective, single-site study of
patients undergoing elective
CABG procedures
317 ASA 7 d before surgery (215)
No ASA (102)
Vuylsteke et al. J Cardiothorac Vasc
Anesth. 1997;11:831-4E12
Prospective, single-site study of
patients undergoing CABG
procedures
144 ASA 7 d before CABG (86)
No ASA (58)
Yende and Wunderink. Crit Care
Med. 2001;29:2271-5E20
Prospective, single-site study of
patients undergoing CABG
procedures
245 ASAþCLO 5 d before CABG (48)
ASA alone (130)
Neither drug (64)
Studies are listed alphabetically. See Table E2 for study findings. ACS, acute coronary syndrome; APT, Antiplatelet; ASA, aspirin; CABG, coronary artery bypass grafting; CLO,
clopidogrel;CPB, cardiopulmonary bypass; d, day(s);DP, dipyridamole; h, hour(s);NR, not reported;OPCABG, off-pump coronary artery bypass grafting; sulf, sulfinpyrazone; tid,
three times daily. aAll CLO and no CLO recipients received ASA; bThe exact percentages of patients taking ASA not reported, although text indicates the use was comparable
between CLO and no CLO groups; c86.4% of CLO recipients received ASA vs 47.3% of no CLO recipients (P<.001); d56% of CLO recipients and 65% of no CLO recipients
received ASA (P¼ not significant); e76.6% of CLO recipients and 79.2% of no CLO recipients received ASA (P not provided); f96.6% of CLO recipients and 94.9% of no CLO
recipients received ASA (P ¼ not significant); g95.5% of CLO recipients and 90.5% of no CLO recipients received ASA (P ¼ not significant).The Journal of Thoracic and Cardiovascular Surgery c Volume 138, Number 4 810.e5
Expert Commentary Aranki and BodyTABLE E4. Large clinical trials assessing the efficacy and safety of dual antiplatelet therapy in acute coronary syndromes
Study Patients
Regimena and
follow-up period
Primary
end point
Absolute
risk reduction Bleeding
CUREE26 12,562 ACS patients CLO (300 mg LD,
75 mg/d MD) vs
placebo for an average
of 9 mo
CV death, nonfatal
MI, or stroke
2.1% (9.3% vs
11.4%; P<.001)
3.7% vs 2.7%b;
P¼ .001
PCI–CUREE27 2658 ACS patients
who underwent PCI
CLO (300 mg LD,
75 mg/d MD) vs
placebo
CV death, MI, or urgent
revascularization
within 30 d of PCI
1.9% (4.5% vs 6.4%;
P¼ .03)
1.6% vs 1.4%b;
P¼ .69
CABG–CUREE28 2072 ACS patients
who underwent
CABG
CLO (300 mg LD,
75 mg/d MD) vs
placebo
CV death, MI,
or stroke
1.7% (14.5% vs
16.2%)c
9.6% vs 7.5%b;
P¼ .095
CREDOE29 2116 patients
undergoing elective
PCI
CLO (300 mg LD,
75 mg/d MD) vs
placebo for 12 mo
All-cause death,
MI, or stroke
3.0% (8.5% vs
11.5%; P¼ .02)
8.8% vs 6.7%d;
P¼ .07
COMMITE30 45,852 STEMI
patients
CLO (75 mg/d MD)
vs placebo
for an average
of 15 days
All-cause death,
reinfarction, or stroke
before hospital
discharge
(up to 4 wk)
0.9% for combined
end point
(9.2% vs 10.1%;
P¼ .002)
0.6% for death
alone
(8.1% vs 7.5%;
P¼ .03)
0.58% vs 0.55%e;
P¼ .59
CLARITYE31 3491 STEMI
patients
CLO (300 mg LD,
75 mg/d MD) vs
placebo for 30 d
Composite of an
occluded
infarct-related artery
on angiography
or all-cause
death or recurrent MI
before angiography
6.7% (15.0% vs 21.7%;
P<.001)
1.3% vs 1.1%d;
P¼ .64
PCI–CLARITYE32 1863 STEMI
patients who
underwent PCI
CLO (300 mg LD,
75 mg/d MD) vs
placebo for 30 d
CV death,
nonfatal MI, or stroke
from PCI to 30 d
2.6% (3.6% vs 6.2%;
P¼ .008)
0.5% vs 1.1%d;
P¼ .21
CABG–CLARITYE33 136 STEMI patients
who underwent
CABG
CLO (300 mg LD,
75 mg/d MD) vs
placebo for 30 d
CV death, MI, or
recurrent ischemia
requiring urgent
revascularization
6.2% (15.2% vs 21.4%;
P¼ .37)
7.6% vs 7.1%d;
P¼1.00
ACS,Acute coronary syndrome;CABG, coronary artery bypass grafting;CLARITY,Clopidogrel as Adjunctive Reperfusion Therapy;CLO, clopidogrel;COMMIT,Clopidogrel and
Metoprolol in Myocardial Infarction Trial; CREDO, Clopidogrel for the Reduction of Events During Observation; CURE, Clopidogrel in Unstable Angina to Prevent Recurrent
Events; CV, cardiovascular; d, day(s); LD, loading dose; MD, maintenance dose; MI, myocardial infarction; mo, month(s); PCI, percutaneous coronary intervention; STEMI,
ST-elevation myocardial infarction; TIMI, Thromboylisis In Myocardial Infarction; wk, week(s). aAll patients received aspirin in addition to either clopidogrel, prasugrel, or
placebo; bCURE criteria for major bleeding (substantially disabling bleeding, intraocular bleeding leading to vision loss, bleeding necessitating transfusion of  2 units of blood);
cP value not provided; 95% confidence interval (0.71–1.11); dTIMI criteria for major bleeding (intracranial bleeding or bleeding associated with a hemoglobin drop  5 g/dL);
eCOMMIT criteria for major bleeding (fatal bleeding, cerebral bleeding, any bleeding that required transfusion).810.e6 The Journal of Thoracic and Cardiovascular Surgery c October 2009
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